mRNA expression
Gene:
JARID1B (official gene symbol)Other symbol:
JARID1BCT family:
CT31CT identifier:
CT31Aliases from NCBI:
FLJ10538 , FLJ12459 , FLJ12491 , FLJ16281 , FLJ23670 , KDM5B , PLU-1 , PUT1 , RBBP2H1AGene expression pattern ? : Testis-selective
Validation by Ludwig Institute of Cancer Research of mRNA expression in normal tissues and cell lines (RT-PCR)
Show![]() | ||
![]() | ||
The figures shown in this section represent a standardized analysis of all reported CT-antigens in the same set of mRNA preparations from
normal human tissues and a selection of human cancer cell lines. The analysis was done by RT-PCR using the primer pairs indicated for each gene.
A total of 1.0 �g of RNA was reverse-transcribed into cDNA using the Omniscript RT kit (Qiagen, Valencia, CA) using oligo (dT)18 primers
(Invitrogen, Carlsbad, CA). JumpStart REDTaq� ReadyMix-(Sigma Aldrich, St. Louis,MO) was used for amplification according to the manufacturer's
instructions. Samples were amplified with a precycling hold at 95oC for 3 min, followed by 35 specific cycles of denaturation at 95oC
for 15 seconds,annealing for 30 seconds (10 cycles at 60oC, 10 cycles at 58oC and 15 cycles at 56oC) and extension at 72oC for 30 seconds followed by a final
extension step at 72oC for 7 minutes. The RT-PCR products were run on 1.5% agarose gels and stained by ethidium bromide. |
Published data of mRNA expression in normal tissues
ShowTissue | Methodology | PMID |
---|---|---|
Testis | Northern blot | 10336460 |
Pancreas | RT-PCR | 20726502 |
Skeletal muscle | RT-PCR | 20726502 |
Placenta | RT-PCR | 20726502 |
Liver | RT-PCR | 20726502 |
Heart | RT-PCR | 20726502 |
Lung | RT-PCR | 20726502 |
Brain | RT-PCR | 20726502 |
Kidney | RT-PCR | 20726502 |
Spleen | RT-PCR | 20726502 |
Thymus | RT-PCR | 20726502 |
Prostate | RT-PCR | 20726502 |
Testis | RT-PCR | 20726502 |
Ovary | RT-PCR | 20726502 |
Small intestine | RT-PCR | 20726502 |
Leukocytes | RT-PCR | 20726502 |
Colon | RT-PCR | 20726502 |
Published data of mRNA expression in neoplasias
Hematologic malignacies Show
Tumor Subtype | Sample type | Frequency | Methodology | PMID |
---|---|---|---|---|
Myeloma |
Newly diagnosed patient | 264/320 (82%) | Microarray | 21738656 |
Myeloma |
Relapse patient | 89/264 (34%) | Microarray |
Breast cancer Show
Tumor Subtype | Sample type | Frequency | Methodology | PMID |
---|---|---|---|---|
Breast carcinoma |
3/39 ( 8%) | qRT-PCR | 12530026 | |
Ductal carcinoma |
12/12 (100%) | in situ hybridization | 10336460 | |
Fibroadenoma |
0/3 (0%) | in situ hybridization | ||
Lactating adenoma |
0/2 (0%) | in situ hybridization | ||
Lobular carcinoma |
2/3 (75%) | in situ hybridization |
Melanocytic lesion Show
Tumor Subtype | Sample type | Frequency | Methodology | PMID |
---|---|---|---|---|
Benign melanocytic nevus |
10/10 (100%) | Northern blot and RT-PCR | 10616211 | |
Melanoma |
0/23 (0%) | Northern blot and RT-PCR |
Published data of mRNA expression in Cell Lines
Show2005-2009© CT Antigens Database